
You've Probably Hit Your Protein Goal: Here's What Experts Think You Need Instead
Similar to counting calories, the protein goals trend has gotten out of hand, causing people to buy expensive protein bars, shakes and slabs of meat. According to Dr. Andrew Freeman, a cardiologist at National Jewish Health in Denver, it's actually "extremely uncommon" if not "nearly impossible" to be deficient in protein, at least in the US, where there's an abundance of food. So what's the deal with this protein push by almost every wellness influencer you follow?
You're likely getting enough protein without even trying
As long as you're not heavily restricting yourself and getting enough calories to fuel your body, you're probably hitting your protein goals just by eating a typical American diet. While some people may need more to feel satisfied and strong or to maximize their muscle gains in the gym, the reality for many Americans might be that they meet their protein requirements through their daily diet. For some, that requirement may be well below 100 grams, which is one elusive protein goal often touted, including by the wellness team here at CNET.
"People are absolutely obsessed with protein," Freeman said, pointing to the fact it's also likely you'll hit your "protein goals" even if you're eating a plant-based diet, so long as it's varied and full. One potentially influencing factor toward the protein goal trend is the rise in interest in the carnivore diet, which prioritizes meat consumption.
"What most people forget is some of earth's biggest and strongest mammals, they're all plant-based," Freeman said. "When was the last time you saw a protein-deficient gorilla or elephant?"
Americans, in particular, have a complicated and sometimes disordered relationship with food – when we're not obsessing over getting enough of something (#proteingoals), we're restricting something else (think the villainization of fats and carbs). Examples of some diets that oscillate between these extremes include the ketogenic diet, the carnivore diet, calorie-counting apps and taking extra time to make complicated drinks in the name of weight loss.
This would be more defensible if we were reaping the health benefits of sticking to these diets, but instead, Americans are leaders in chronic diseases such as heart disease and diabetes (preventable and often reversible through diet). Many people also suffer a reduced quality of life from restricting themselves or following diets that may or may not meaningfully improve their health down the line, and may also inspire shame or eating disorders.
Not to mention, most of us are actually deficient in fiber, and a good chunk of us are low in other very important nutrients, such as iron, vitamin D and more. In fact, all the focus on protein ends up causing people to overlook other nutrients their body needs that they can't get from protein. Fiber, for example, is a key carbohydrate that is found mainly in plants and should also be prioritized, especially with the rising rates in colorectal cancer among people younger than 50 years old.
Of course, this is absolutely not to say that protein isn't important, or that some people need more than others based on their activity level or the muscle build they're going for. Here, we merely take a minute to plead the case that, when it comes to protein, you may be able to cool it a bit.
How much protein should you actually be eating?
Look, the intro to this topic came on a little strong, so it is important to take a moment and stress how protein is an absolutely vital nutrient: protein contains amino acids, which build our bodies and help them function. If we didn't eat protein, we'd be dead.
To get a baseline of how much we need to support our needs, there's fortunately a recommended daily amount, or RDA, of protein. This is 0.8-gram of protein per kilogram of body weight. (There are about 2.2 pounds in one kg.) This means a person who weighs 200 pounds needs about 73 grams of protein to meet their needs and not be deficient.
Where it gets tricky is deciphering exactly how much protein you need not only to stay alive, but to thrive. Like every health "thing," what's best for you will depend on your body and your activity level, for example. But even taking this into account, you may not have to work as hard as you think to get adequate protein, even if you're hitting the gym regularly.
In a 2023 podcast hosted by Zoe, a nutrition science company and maker of at-home gut microbiome test kits, Stanford University professor and nutrition researcher Christopher Gardner explained why fears of falling short in the protein department are often overblown.
"When the US comes up with recommended daily allowances for protein, vitamins and minerals, the standard approach is to take two standard deviations above the average," Gardner explained in the podcast. For the 0.8-gram of protein per kilogram of weight, he said, "You've picked a number that should be adequate for 97.5% of the population."
But what if you're above average? Chances are, you're not.
"To me, it's the American idea of 'that's what the RDA is, but I know I'm above average, so let me make sure I get some extra here,'" Gardner explained.
"It was built in to recognize that some people need more [protein]," he continued, going on to explain that when you're working out heavily, you're naturally going to feel hungrier, which will prompt you to eat more -- which means (for most people), naturally eating more protein.
But what if you want to really gain muscle? To its credit, and in a refreshing turn of American-diet events, the protein goal trend is focused on adding rather than restricting. And if you're into intense weightlifting, or if you want to gain muscle, you will need more. But chances are that "more" is not as much more as you might think -- at least if you're considering consciously adding protein through shakes and other supplements.
If you really want to build muscle or are seriously into weight lifting, estimates on how much "extra" protein you need varies, and the best (and safest) advice is always to talk to your doctor or nutritionist to take your whole health and lifestyle into account. But some estimates land around 1.2 to 1.7 grams per kilogram of weight. Others are even higher, at up to 2 grams per kilogram.
This discussion assumes you enjoy counting your macros, though. If you eat when you're hungry, fuel up after a hard workout and choose foods that are rich in protein and also part of a well-balanced diet, you should be good to go.
In addition to weightlifting, Freeman said that people with medical concerns, such as undergoing surgery or recovering from burns, need more protein. Pregnancy and older adulthood are other instances when people's protein requirement goes up a bit in relation to their calorie intake.
Yaorusheng/Moment via Getty Images
Can you get too much protein? What about protein's benefits?
High protein consumption makes the kidneys work harder, which may be a concern for some and is one reason parents should be wary of giving kids extra protein supplements, according to the Cleveland Clinic.
However, hitting your high protein goals or even exceeding them shouldn't be harmful for most people, though keep in mind that after they're broken down into those vital amino acids and the energy is expended, excess protein is stored as fat if not used for energy.
Now for a benefit: In addition to overall body function and muscle building, protein is very filling and satiating. This means a protein-rich meal may aid in weight loss (if that's your goal) because it keeps you full for longer when compared, for example, to a meal that's more carb-heavy and lacking in protein.
Craving protein? You could be low in iron
About 95% of Americans aren't eating enough fiber, according to research from 2016. Fiber is found in plant-based foods such as vegetables, fruits, whole grains, seeds and more.
Nearly one in three of us are also low in iron, which is where things get interesting in the protein discussion, because excellent sources of protein are often excellent sources of iron. (Steak and other red meat, for example.) However, there are plant-based foods like dark greens that are high in iron and also in fiber.
Vitamin D, a nutrient we can get from the sun as well as from our food, is also one Americans tend to be lower in. This is especially notable during the cooler months.
Unfortunately, the advice for how to best meet your nutritional needs isn't flashy and mimics previous guidance: Eat a full diet full of variety and color, prioritizing foods like vegetables, healthy fats and, yes, protein.
You just don't need to obsess about it.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
5 minutes ago
- Medscape
Optimizing Therapies for HR+ Early-Stage Breast Cancer
Hormone receptor-positive (HR+) early-stage breast cancer is one of the most common types of breast cancer, characterized by tumor cells that have receptors for estrogen or progesterone hormones. Although significant progress has been made in screening, treatment, and surgery, the risk of recurrence still remains. To explore therapies for managing HR+ early-stage breast cancer, Medscape spoke with Hope S. Rugo, MD, FASCO, division chief of breast medical oncology and a professor of medical oncology and therapeutics research at City of Hope Comprehensive Cancer Center, Duarte, California, and professor emeritus at the University of California San Francisco. Read on for her insights. What role does risk stratification play in determining therapy for HR+ early-stage breast cancer? Hope S. Rugo, MD, FASCO This is a critical area. It is a key aspect of determining appropriate treatment and extent of treatment, and we are still learning more about how to appropriately stratify based on clinicopathologic and genomic characteristics. Gene expression tests are used widely to understand prognosis and benefit from chemotherapy, but there are ongoing issues in HR+ disease including disease heterogeneity and how to optimally treat very young women with HR+ disease. We use clinicopathologic data in combination with gene expression tests to stratify risk, but this approach doesn't always provide us with the necessary information for determining the optimal adjuvant or neoadjuvant treatment. The adjuvant CDK4/6 inhibitor trials will be helpful, as they will allow for longer follow-up of patients with high- and intermediate-risk disease. Additionally, newer predictors, such as gene expression signatures that may estimate the benefit from immunotherapy, are also being evaluated. What factors influence your choice between endocrine therapy and chemotherapy for HR+ early-stage breast cancer? Multiple factors have an influence on the choice of therapy, including the extent of disease and tumor biology. We have also learned that the intensity or extent of estrogen positivity plays a role in endocrine sensitivity. In terms of tumor biology, understanding tumor proliferation and chemotherapy sensitivity is critical. We are currently using gene expression tests, but it is clear that these are insufficient, even within the context of age and tumor burden. Additional markers that help to identify up-front or emerging resistance to endocrine therapy are critical. Data from the CDK4/6 inhibitor adjuvant trials has further complicated this question — as now the issue is where optimal outcome can be achieved in less chemotherapy-responsive, higher-risk disease with the addition of abemaciclib or ribociclib. Considering recent research, is extended endocrine therapy actually beneficial? I believe it is, but careful consideration needs to be given to the decision to extend therapy. Disease burden is of course our first consideration, but sensitivity to endocrine therapy, development of resistance, and response to chemotherapy in appropriate cases need to be taken into consideration. Interestingly, several analyses have suggested that patients with low proliferative and genomic risk, but a higher disease burden, might be most likely to benefit from extended duration endocrine therapy due to the long natural history of this disease. We are now exploring the use of switching the type of endocrine therapy in the high-risk adjuvant setting and the use of circulating tumor DNA (ctDNA) to optimize therapy. What role do CDK4/6 inhibitors play in the adjuvant setting for HR+ early-stage disease? Both abemaciclib and ribociclib have reduced the risk of recurrence and the risk of distant recurrence in patients with intermediate or high-risk early-stage breast cancer. The duration of therapy varies, and eligibility criteria overlap; however, the recent NATALEE trial included a diverse population, including an intermediate-risk group (stage II, node-negative with additional risk factors) to evaluate the role of the CDK4/6 inhibitors among such populations. The striking aspect of this trial was the carry-over effect, shown most clearly in the monarchE study with 5-year follow-up. Even 3 years after completing treatment with abemaciclib, the data showed an increasing impact on disease-free survival and distant disease-free survival. Although there has been no overall survival impact yet, fewer patients with abemaciclib in monarchE are living with metastatic disease. What are the most critical research gaps or upcoming trials that could reshape how we manage HR+ early-stage breast cancer in the upcoming years? A few main things to address are improving risk stratification, how to use ctDNA to improve outcome, and understanding if use of oral selective estrogen receptor degrader (SERDs) in sequence improve outcome and their optimal therapy duration. So far, studies using ctDNA to assess risk and guide therapy changes have been challenging due to the low number of positive ctDNA results. Moreover, ctDNA detection has sometimes coincided with metastatic disease already visible on scans in case of several aggressive cancers. We still don't know the optimal treatment approach when molecular evidence of disease is found, which is making studies focus on adding targeted therapy or changing endocrine therapy. Several trials are evaluating oral SERDs in the early stage setting for the treatment of high-risk disease. While these trials will also collect ctDNA, patient eligibility is not based on these tests. One very important area that requires additional research is understanding early-stage breast cancer in young women, where tumors seem to behave poorly — particularly in women under the age of 40 — even when patients are treated with optimal therapy. Understanding optimal therapy is a key research focus, and further investigation of biological drivers in both ductal and lobular cancers is warranted. The OFFSET trial aims to determine the value of adjuvant chemotherapy vs ovarian function suppression in conjunction with standard endocrine therapy and CDK4/6 inhibitors as indicated. However, this study is challenging to enroll in. Hope S. Rugo, MD, FASCO, has disclosed the following relevant financial relationships: Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Chugai; Puma; Sanofi; Napo; Mylan Received research grant from: AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Stemline Therapeutics; OBI Pharma; Ambrx


Fast Company
5 minutes ago
- Fast Company
Wegovy and Zepbound patients are resorting to these cost-saving measures to stay on the weight-loss drugs
Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but as more U.S. insurers restrict coverage people are trimming costs by stretching doses or forgoing expenditures like vacations to pay for the medication out of pocket. A half dozen doctors who spoke with Reuters said insurance coverage has tightened in 2025 as many employers drop it for the expensive GLP-1 drugs. While patients on these medications are counseled on proper diet and exercise, clinical trials show that people who stop taking these drugs are apt to regain weight. Novo Nordisk's Wegovy and Eli Lilly's Zepbound are weekly injections with U.S. insurer list prices of more than $1,000 a month. For customers willing to pay cash, both drugmakers will ship directly for $499 a month if refills are purchased at fixed intervals. 'A significant number of my patients now pay cash,' said Dr. Nidhi Kansal, an obesity specialist at Northwestern Medicine in Chicago. 'People find a way to scrounge up $6,000 a year, which sucks, because that's a vacation or two.' Subscribe to the Daily newsletter. Fast Company's trending stories delivered to you every day Privacy Policy | Fast Company Newsletters More than a billion people worldwide are obese, according to the U.N. World Health Organization, which has said the GLP-1 drugs could help end the obesity pandemic. 'A KIND OF PURGATORY' A tech industry job change for Yelena Kibasova, a 40-year-old who lives in the Minneapolis area, meant loss of coverage for her Zepbound prescription that helped her achieve and maintain a 150-pound (68-kg) weight loss. GLP-1 patient Yelena Kibasova, 40, poses in this undated handout picture. [Photo: @morethanmyweight/Handout via Reuters] 'My new company does not cover GLP-1s, so now I am in a kind of purgatory,' Kibasova said. 'I stopped doing my nails. I stopped doing my hair. Those things are not as important as me staying at a healthy weight.' The doctors interviewed by Reuters said patients once leery about long-term obesity treatment are now more comfortable staying on a drug. The doctors said that conversations about temporary use happen only when a patient is trying to lose a certain amount of weight for issues such as fertility treatment or an organ transplant. These obesity specialists said they are hopeful that competition will help bring down prices as new weight-loss options emerge, including new oral drugs that may be available next year. Lilly last week announced trial results for its easier-to-manufacture pill, which was shown to cut patient weight by 12.4%, a few percentage points less than injected drugs. The company hopes to launch it in August 2026. Kenneth Custer, Lilly's head of cardiometabolic health, told Reuters the pill is being tested in several settings, including as a maintenance therapy. Custer declined to comment on how it might be priced. MEDICATION FOR MAINTENANCE Dr. Anne Peters, an endocrinologist at Keck Medicine USC in Los Angeles, said it is important that patients who reach their weight-loss goal not stop a prescription 'cold turkey,' so the dose can be tapered down over several months. Peters said about a third of her patients are able to reduce their dose and maintain weight loss, while the rest need to stay on the medication. An analysis of U.S. pharmacy insurance claims found that nearly two-thirds of patients who started on Wegovy or Zepbound in 2024 were still on the medications a year later. advertisement Peters said she uses 'every technique in the book' to secure insurance coverage for patients, but noted that a growing number of plans no longer pay for the treatments, and patients have to pay out-of-pocket. U.S. pharmacies supply self-injection pens pre-loaded with doses of Wegovy or Zepbound. Lilly's direct-to-consumer service also offers vials. 'Some patients can stretch out the vials longer. Get 15 mg, and then give a 10 mg dose for instance,' Dr. Peters said, noting that the drug's instructions advise that such an approach should not be taken. Doses of 5 mg, 10 mg and 15 mg are recommended for weight-loss maintenance. Patients also are turning to lower-cost compounded versions of the GLP-1 drugs, or are even mixing them at home with raw ingredients, both of which Peters and other doctors advise against due to safety concerns. Dr. Angela Fitch, former president of the Centennial, Colorado-based Obesity Medicine Association and chief medical officer at online primary care provider Knownwell, said nobody wants to be on a medication, but patients who respond to a GLP-1 drug 'really don't want to go off of it when they recognize that it has such a value to them.' Both Wegovy and Zepbound were first launched, under the brand names Ozempic and Mounjaro, as diabetes treatments. The class has been linked to a range of benefits, including improved heart health and less sleep apnea. Fitch said the most common reason for her patients to stop taking a GLP-1 drug is loss of insurance coverage. She said her experience is that about 10% of patients are able to reach a target weight and maintain it without further treatment. 'We are in a dip where people are dropping coverage,' Fitch said, adding that the direct-to-consumer options are an 'upper-ish middle-class thing.' —Deena Beasley, Reuters


Fox News
7 minutes ago
- Fox News
Cowboys' Jerry Jones reveals scary skin cancer battle
Dallas Cowboys team owner Jerry Jones revealed he overcame an off-the-field battle as he holds out hope that the organization he helped make one of the most valuable in sports reaches the Super Bowl once more. Jones revealed in an interview with the Dallas Morning News that he was diagnosed with stage 4 melanoma skin cancer in June 2010 and started his treatment soon after. The report noted that Jones slightly touched on undergoing cancer treatments a "dozen years ago" during one of the episodes of the Netflix docuseries "America's Team: The Gambler and His Cowboys." "I was saved by a fabulous treatment and great doctors and a real miracle (drug) called PD-1 (therapy)," he told the Morning News. "I went into trials for that PD-1 and it has been one of the great medicines. "I now have no tumors." Jones said he's had four surgeries over the last 10 years – two on his lungs and two to deal with his lymph nodes. Melanoma is a less common form of skin cancer that is more dangerous than other varieties because it's much more likely to spread to other parts of the body if not found and treated early, according to the American Cancer Society. The Melanoma Research Alliance said stage 4 means the cancer "metastasized (spread) to other places throughout the body, such as the brain, lungs, liver, or gastrointestinal (GI) tract." "The 5-year survival rate as of 2018 for distant metastatic (Stage IV) melanoma is 22.5%," the research organization stated on its website. Jones, 82, is set to embark on another NFL season as the head of the Cowboys. Sportico revealed its NFL valuations on Wednesday with the Cowboys leading the league at $12.8 billion.